Study study type PathologyT1T0Patientssample sizesROB Results

mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population

versus BSC
avelumab alone
JAVELIN Bladder 100 (all population), 2020
  NCT02603432
RCTmUC - M - all populationavelumabBSCas first line therapy, previously untreated locally advanced or metastatic urothelial carcinoma whose disease did not progress on induction chemotherapy350 / 350some concern
conclusif
  • demonstrated 31 % decrease in deaths (OS) (PE)
  • suggested 24 % decrease in deaths (OS) (extension)
  • suggested 46 % decrease in PFS (extension)
  • suggested 38 % decrease in progression or deaths (PFS)